Quantitative Immunological Assays to Assess HIV Antibodies and Vaccines
评估 HIV 抗体和疫苗的定量免疫分析
基本信息
- 批准号:10712581
- 负责人:
- 金额:$ 89.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AnimalsAntibodiesBiological AssayClinical TrialsDataData AnalysesGenesHIVHIV AntibodiesHIV vaccineHIV-1Immune responseImmunology procedureIndividualIndustry CollaborationInfectionInfrastructureLiquid substanceNational Institute of Allergy and Infectious DiseasePersonsProtocols documentationReagentRoboticsRoleRunningSamplingSerumServicesStandardizationVaccinatedVaccine ResearchVaccinesVariantVirusWorkantibody engineeringantibody testcandidate selectionclinical candidateimprovedmanufacturabilitymutantneutralizing antibody
项目摘要
We are a Core lab providing HIV antibody assay services to labs within the Vaccine Research Center, other intramural labs, and for collaborators around the world. Most of our work uses a standardized HIV-1 neutralization assay. We perform this assay on serum samples from vaccinated animals and HIV-infected individuals, on antibodies isolated from such subjects, and on variant antibodies engineered for improved breadth, potency, and manufacturability. We also develop and maintain the reagents needed for these assays, including natural and mutant virus genes, stocks of viruses, and stocks of reference antibodies. We recently have increased the throughput of our assay by integrating robotic liquid handling into our protocols. In addition, we provide analysis and graphics to allow interpretation of our data, as well as related data from the VRC VIP lab; these are being used for selection of candidate clinical products at the VRC and by collaborators. We also provide data to collaborators at a pharma company to inform their decisions on developing products for clinical trials.
我们是一个核心实验室,为疫苗研究中心内的实验室、其他内部实验室以及世界各地的合作者提供艾滋病毒抗体检测服务。我们的大部分工作都使用了标准化的HIV-1中和试验。我们对接种疫苗的动物和HIV感染者的血清样本、从这些受试者分离的抗体以及为提高广度、效力和可制造性而设计的变异抗体进行这种检测。我们还开发和维护这些检测所需的试剂,包括天然和突变病毒基因、病毒库存和参考抗体库存。我们最近通过将机器人液体处理集成到我们的方案中,增加了我们的检测的吞吐量。此外,我们还提供分析和图表来解释我们的数据,以及来自VRC VIP实验室的相关数据;这些数据正被VRC和合作者用于选择候选临床产品。我们还向一家制药公司的合作者提供数据,为他们开发临床试验产品的决定提供信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard A Koup其他文献
HIV integration and T cell death: additional commentary
- DOI:
10.1186/1742-4690-10-150 - 发表时间:
2013-12-09 - 期刊:
- 影响因子:3.900
- 作者:
Arik Cooper;Mayra García;Constantinos Petrovas;Takuya Yamamoto;Richard A Koup;Gary J Nabel - 通讯作者:
Gary J Nabel
Richard A Koup的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard A Koup', 18)}}的其他基金
Tfh and B cells in HIV/SIV pathogenesis and vaccination
Tfh 和 B 细胞在 HIV/SIV 发病机制和疫苗接种中的作用
- 批准号:
10497724 - 财政年份:
- 资助金额:
$ 89.24万 - 项目类别:
Tfh and B cells in HIV/SIV pathogenesis and vaccination
Tfh 和 B 细胞在 HIV/SIV 发病机制和疫苗接种中的作用
- 批准号:
8745610 - 财政年份:
- 资助金额:
$ 89.24万 - 项目类别:
T Cell Immune Responses To HIV And Other Pathogens
T 细胞对 HIV 和其他病原体的免疫反应
- 批准号:
8336373 - 财政年份:
- 资助金额:
$ 89.24万 - 项目类别:
Pre-clinical Vaccine Development for Respiratory Viruses
呼吸道病毒临床前疫苗开发
- 批准号:
10712583 - 财政年份:
- 资助金额:
$ 89.24万 - 项目类别:
Tfh and B cells in HIV/SIV pathogenesis and vaccination
Tfh 和 B 细胞在 HIV/SIV 发病机制和疫苗接种中的作用
- 批准号:
9161747 - 财政年份:
- 资助金额:
$ 89.24万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 89.24万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 89.24万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 89.24万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 89.24万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 89.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 89.24万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 89.24万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 89.24万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 89.24万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 89.24万 - 项目类别:














{{item.name}}会员




